Uninformed consent: mass screening for prostate cancer

Area of Science:

• Urology
• Oncology
• Medical Ethics

Background:

• Informed consent is a cornerstone of ethical medical practice, particularly for cancer screening.
• Prostate cancer screening, primarily via Prostate-Specific Antigen (PSA) testing, is widespread but often lacks comprehensive patient understanding of its limitations.

Purpose of the Study:

• To highlight the deficit in informed consent for prostate cancer screening.
• To discuss the potential generational consequences of PSA testing, including overdiagnosis and overtreatment.

Main Methods:

• Literature review and critical analysis of current prostate cancer screening practices.
• Examination of the implications of PSA testing on patient understanding and family risk stratification.

Main Results:

• Prostate cancer screening via PSA testing frequently occurs without adequate patient comprehension of its potential harms, such as uncertain mortality benefits and detection of indolent cancers.
• The diagnosis of prostate cancer in a father, even if clinically insignificant, elevates his son's risk category, potentially leading to increased surveillance and a higher likelihood of overdiagnosis.

Conclusions:

• The widespread practice of PSA testing, often without full informed consent, carries significant risks of overdiagnosis and overtreatment.
• The generational impact of prostate cancer diagnosis and treatment, particularly on sons of affected men, has been overlooked in medical discourse.
• There is a critical need to address the ethical and practical shortcomings of informed consent in prostate cancer screening to mitigate intergenerational harm.